Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 17 Brain Neoplasms 8 Neoplasms 5 Glioma 5 Recurrence 3 Astrocytoma 3 Solid Tumor 1 Sarcoma 1 Pancreatic Neoplasms 1 Neoplasm Recurrence, Local 1 Neoplasm Metastasis 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia-Lymphoma, Adult T-Cell 1 Kidney Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Camurati-Engelmann Syndrome 1 Breast Neoplasms 1 Bone Neoplasms 1

Interventions

Injections 10 pembrolizumab 8 Paclitaxel 8 Docetaxel 7 senaparib 6 Nivolumab 6 Cisplatin 5 Capecitabine 5 toripalimab 4 atezolizumab 4 Ipilimumab 4 Gemcitabine 4 tislelizumab 3 Rifampin 3 Itraconazole 3 Carboplatin 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 pertuzumab 2 magrolimab 2 fluzoparib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2 Oxaliplatin 2 Midazolam 2 Leucovorin 2 Irinotecan 2 Fluorouracil 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡